Parkinson’s disease psychosis—hallucinations and/or delusions—affects up to half of people with Parkinson’s disease and can begin subtly (eg, a “sense of presence”) before progressing to vivid visions or fixed false beliefs. Because these symptoms often go unreported due to stigma, routine check-ins with patients and care partners are essential for early detection and individualized management alongside motor symptom care. Early education about these non-motor symptoms—and about common triggers such as infections, medication changes, or poor sleep—can encourage earlier reporting and help families anticipate flares.
Clinicians face the challenge of treating psychosis without worsening motor control. Pimavanserin is the only FDA-approved therapy for Parkinson’s disease psychosis. In trials, pimavanserin reduced hallucination/delusion severity without measurable motor decline at 6 weeks. Long-term safety/open-label and real-world retrospective data are available, and effective care hinges on proactive, empathetic conversations that normalize non-motor symptoms and align treatment decisions with patient and caregiver goals. Nonpharmacologic measures—optimizing vision and sleep, reducing nighttime stimuli, and simplifying environments—can be paired with medication to improve outcomes.
Reference: Dashtipour K. Managing Parkinson’s Disease–Related Hallucinations and Delusions. Neurology Live. Published September 18, 2025. Accessed October 2, 2025. https://www.neurologylive.com/view/managing-parkinson-s-disease-related-hallucinations-and-delusions
Link: https://www.neurologylive.com/view/managing-parkinson-s-disease-related-hallucinations-and-delusions
